Articles related to DEVICE/DRUG APPROVALS

“Families and health care professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection free days per year for their children 2.5 years and older with ISS, NS, and born SGA,” said Dr Aristides Maniatis, Founder, Rocky Mountain Pediatric Endocrinology.

Foundayo will be available via LillyDirect beginning April 6, with widespread availability through retail pharmacies and telehealth providers occurring soon after.

“Hidradenitis suppurativa (HS) affects far more than skin; it impacts confidence, emotional well-being and relationships during a formative period for many pediatric patients.” – Brindley Brooks, Founder & CEO, HS Connect.

The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.

Reproxalap is an investigational drug candidate for the treatment of dry eye disease.

TECNIS PureSee IOL is the first and only US FDA‑approved extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity